- US-based pharmaceutical company Merck (NYSE: MRK) has presented results of a Phase 3 trial evaluating the efficacy and safety of Belsomra (suvorexant)
C-IV for the treatment of insomnia in people with mild-to-moderate Alzheimer's disease dementia, the company said.
United States-based Merck has revealed results of a phase three trial assessing the efficacy and safety of BELSOMRA (suvorexant)
C-IV intended for the treatment of insomnia in people with mild-to-moderate Alzheimer's disease dementia, it was reported yesterday.
HA, LN,
C-IV and PIII NP were detected by using diagnostic kits.
The county has trained librarians, food bank volunteers, local pharmacy staff and others to assist people in using
C-IV and kiosk applications.
Revised labeling including a boxed warning for Redux (dexfenfluramine hydrochloride capsules)
C-IV, which is marketed by Wyeth-Ayerst, has also been submitted to the FDA because it is a related chemical compound to fenfluramine.
Pharmaceutical company Dr Reddy's Laboratories (NYSE:RDY) stated on Wednesday that it has introduced its US Food & Drug Administration (USFDA) approved Eszopiclone Tablets (
C-IV) 1 mg, 2 mg and 3 mg in the US market.
M2 EQUITYBITES-November 24, 2011-Transcept Pharmaceuticals Inc awarded FDA approval of Intermezzo
C-IV for middle-of-the-night insomnia(C)2011 M2 COMMUNICATIONS http://www.m2.com
24 November 2011 - US Transcept Pharmaceuticals Inc (NASDAQ:TSPT) said on Wednesday the US Food and Drug Administration (FDA) had approved Intermezzo (zolpidem tartrate sublingual tablet)
C-IV for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.